Vulvar Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Vulvar Cancer – Pipeline Review, H2 2016’, provides an overview of the Vulvar Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vulvar Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Vulvar Cancer

The report reviews pipeline therapeutics for Vulvar Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Vulvar Cancer therapeutics and enlists all their major and minor projects

The report assesses Vulvar Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Vulvar Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Vulvar Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vulvar Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Cutanea Life Sciences Inc

ISA Pharmaceuticals BV

Ono Pharmaceutical Co Ltd

Oryx GmbH & Co KG

PDS Biotechnology Corp

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Vulvar Cancer Overview 6

Therapeutics Development 7

Pipeline Products for Vulvar Cancer - Overview 7

Pipeline Products for Vulvar Cancer - Comparative Analysis 8

Vulvar Cancer - Therapeutics under Development by Companies 9

Vulvar Cancer - Therapeutics under Investigation by Universities/Institutes 10

Vulvar Cancer - Pipeline Products Glance 11

Clinical Stage Products 11

Vulvar Cancer - Products under Development by Companies 12

Vulvar Cancer - Products under Investigation by Universities/Institutes 13

Vulvar Cancer - Companies Involved in Therapeutics Development 14

Cutanea Life Sciences Inc 14

ISA Pharmaceuticals BV 15

Ono Pharmaceutical Co Ltd 16

Oryx GmbH & Co KG 17

PDS Biotechnology Corp 18

Vulvar Cancer - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

ISA-101 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

nivolumab - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

omiganan pentahydrochloride - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

PDS-0101 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Vicoryx - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Vulvar Cancer - Dormant Projects 72

Vulvar Cancer - Product Development Milestones 73

Featured News & Press Releases 73

Oct 05, 2011: FDA Grants ISA Pharmaceuticals Orphan Drug Designation For Treatment Of Vulvar Intraepithelial Neoplasia With ISA-HPV-SLP 73

Mar 07, 2011: ISA Pharma Receives €2.7m From Dutch Government To Further Clinical Development Of HPV-SLP Vaccine 73

Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 73

Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 74

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76

List of Tables

List of Tables

Number of Products under Development for Vulvar Cancer, H2 2016 7

Number of Products under Development for Vulvar Cancer – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Products under Investigation by Universities/Institutes, H2 2016 13

Vulvar Cancer – Pipeline by Cutanea Life Sciences Inc, H2 2016 14

Vulvar Cancer – Pipeline by ISA Pharmaceuticals BV, H2 2016 15

Vulvar Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 16

Vulvar Cancer – Pipeline by Oryx GmbH & Co KG, H2 2016 17

Vulvar Cancer – Pipeline by PDS Biotechnology Corp, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Vulvar Cancer – Dormant Projects, H2 2016 72

List of Figures

List of Figures

Number of Products under Development for Vulvar Cancer, H2 2016 7

Number of Products under Development for Vulvar Cancer – Comparative Analysis, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports